Tenaya Therapeutics (TNYA) Enterprise Value (2021 - 2026)

Tenaya Therapeutics has reported Enterprise Value for 6 years, with the latest figure at $87.8 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 214.31% year-over-year to $87.8 million in Q2 2026; TTM through Jun 2026 was $87.8 million, a 214.31% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, down 86.69% from the prior year.
• Enterprise Value was $87.8 million for Q2 2026 at Tenaya Therapeutics, up from $69.4 million in the prior quarter.
• The five-year high for Enterprise Value was $288.4 million in Q1 2024, with the low at -$96.4 million in Q4 2022.
• Average Enterprise Value over 5 years is $90.6 million, with a median of $65.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value plunged 213.77% in 2022, then soared 574.36% in 2024.
• Over 5 years, Enterprise Value stood at -$96.4 million in 2022, then surged by 221.07% to $116.7 million in 2023, then slumped by 46.63% to $62.3 million in 2024, then sank by 86.69% to $8.3 million in 2025, then surged by 959.21% to $87.8 million in 2026.
• The last three Enterprise Value figures came in at $87.8 million (Q2 2026), $69.4 million (Q1 2026), and $8.3 million (Q4 2025), per Business Quant data.